[The analysis of CCR4+/CXCR3+ cell ratio in gastrointestinal cancer patients receiving chemotherapy or immunotherapy].
We investigated the expression of CCR4 and CXCR3 with the peripheral blood lymphocytes in 31 gastrointestinal cancer patients who received either chemotherapy or immunotherapy. The expressions of CXCR3 were 6.8% in the patients received chemotherapy and 24.2% in the patients received immunotherapy. The expressions of CCR4 were 25.6% in the patients received chemotherapy and 15.4% in the patients received immunotherapy. The ratio of CCR4+/CXCR3+ cells was 4.45 in chemotherapy and 0.72 in immunotherapy. These results suggested that it was the Th2 dominant condition in the patients received chemotherapy and the Th1 dominant condition in the patients received immunotherapy.
Sakuyama
Ryuji
R
Dept. of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University.
Aruga
Atsushi
A
Kuramochi
Hidekazu
H
Matsushita
Norimasa
N
Kotera
Yoshihito
Y
Takeshita
Shingo
S
Hayashi
Kazuhiko
K
Yamamoto
Masakazu
M
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D054398:Receptors, CCR4 / Q000378:metabolism*; D054367:Receptors, CXCR3 / Q000378:metabolism*
D000970:Antineoplastic Agents; C515354:CCR4 protein, human; C515187:CXCR3 protein, human; D054398:Receptors, CCR4; D054367:Receptors, CXCR3